“Brief Summary” Requirement Is Legally Vulnerable, Attorney Tells WLF
Executive Summary
FDA's policy that a brief summary must accompany print advertising is vulnerable to legal challenge, attorney Richard Frank (Olsson, Frank & Weeda) declared during a Washington Legal Foundation briefing on First Amendment issues May 30
You may also be interested in...
DTC And FDA: “Brief Summary” Improvements Are Priority For McClellan
FDA will address physicians' "legitimate" concern that direct-to-consumer ads do not provide balanced risk-benefit information, Commissioner McClellan told the National Association of Health Underwriters legislative conference March 25 in Washington, D.C
DTC And FDA: “Brief Summary” Improvements Are Priority For McClellan
FDA will address physicians' "legitimate" concern that direct-to-consumer ads do not provide balanced risk-benefit information, Commissioner McClellan told the National Association of Health Underwriters legislative conference March 25 in Washington, D.C
FDA Drug Ad Rulings Do Not Need To Rely On Consumer Survey Data – Troy
FDA decisions on whether direct-to-consumer drug ads are false or misleading do not need to be backed with consumer comprehension data, Chief Counsel Daniel Troy said